新冠疫苗接种与新发或复发性类风湿关节炎的信号检测研究
本研究利用国际药物警戒数据库VigiBase进行病例-非病例分析,比较新冠疫苗与其他非活疫苗接种后类风湿关节炎(RA)的报告风险,并在法国药物警戒数据库(FPVD)中描述性分析RA病例。VigiBase中新冠疫苗相关RA的报告比值比为0.66(P<0.0001),未显示较其他非活疫苗更高的RA风险;FPVD报告161例RA病例,其中新发77例、复发84例。
要点
- VigiBase中新冠疫苗相关RA的报告比值比为0.66(P<0.0001),未显示高于其他非活疫苗的风险。
- FPVD报告161例新冠疫苗相关RA病例,其中新发77例、复发84例。
- 88例(84.7%)RA发生在第一剂接种后,新发RA可能起病更快、更重、结局更差。
核心结论
- 在成人中,未显示新冠疫苗接种后RA风险高于其他非活疫苗。
- 新发RA比RA复发更可能快速发生、更严重且结局更差。
研究设计与样本
- 在国际药物警戒数据库VigiBase中采用病例-非病例方法,比较新冠疫苗与其他非活疫苗后RA的报告风险。
- 利用法国药物警戒数据库(FPVD)对新冠免疫后RA病例进行描述性分析,并用多变量logistic回归比较新发与复发组的变量。
主要发现
- 2021年VigiBase中新冠疫苗相关不良反应记录2,817,902例,其中报告RA病例2,387例。
- 新冠疫苗与其他非活疫苗相比,RA发生的报告比值比为0.66(P<0.0001)。
- FPVD报告161例新冠疫苗相关RA病例,包括77例新发RA和84例RA复发。
- 88例(84.7%)RA发生在第一剂接种后,接种至发病平均时间为14±21天,复发组延迟显著更短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
COVID-19 vaccination is critical in frequently immunocompromised patients with rheumatoid arthritis (RA). However, there is a question about the risk of RA flares following vaccination. Our study intended to find out about cases of new RA or flare-ups in people who already had RA that were reported in French and international pharmacovigilance databases after COVID-19 vaccination. We performed a "case-noncase" method in the international pharmacovigilance database VigiBase to identify the risk of RA following COVID-19 vaccination compared with other nonlive vaccines. Using the French Pharmacovigilance Database (FPVD), a descriptive analysis was carried out for RA cases after COVID-19 immunization and a multivariate logistic regression analysis was conducted to compare variables in the new-onset vs. flare-up groups. In 2021, 2,387 cases of RA were reported from 2,817,902 adverse drug reactions associated with COVID-19 vaccines recorded in VigiBase. The reporting odds ratio of RA onset with COVID-19 vaccines compared with the other nonlive vaccines was 0.66 (P < 0.0001). The FPVD reported 161 cases of RA with COVID-19 vaccines, including 77 new-onset RA and 84 cases of RA flare-up. In 88 cases (84.7%), RA occurred after the first dose. The mean time between vaccination and disease onset was 14 ± 21 days, and the delay was significantly shorter in the flare-up group. We do not show a higher risk of RA after COVID-19 vaccination compared with other nonlive vaccines in adults. De novo RA was more likely to happen quickly, be more severe, and have a worse outcome than flares in patients with RA.
引用
- Prontskus V, Fresse A, Yelehe-Okouma M, et al. COVID-19 Vaccination and the Incidence of De Novo or Recurrent Rheumatoid Arthritis: A French and International (VigiBase) Signal Detection Study. Clin Pharmacol Ther. 2023. PMID: 36752604. doi:10.1002/cpt.2866
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。